LTS LOHMANN Therapie-Systeme AG (LTS) and Grand River Aseptic Manufacturing (GRAM) entered a strategic alliance focused on sterile fill finish for containers used in LTS’ Sorrel wearable injector devices. This collaboration aims to offer pharmaceutical companies a comprehensive solution for both the development and manufacturing of wearable injectors specifically designed for the delivery of biologics. With an integrated approach from concept to completion, the goal is to facilitate faster market access and streamlined production processes.
The CDMO Roundtable at CPHI North America featured industry experts in a panel discussion which covered the newest developments in outsourcing, including industry trends, technological advancements, regulatory considerations and strategic partnerships.
Grand River Aseptic Mfg Adds 150,000 Sq Ft Syringe And Cartridge Filling Center
Investing In the Right Equipment for Tech Transfer Excellence
Finished Product InsP: Automation, Complex Therapeutics, Quality Standards
Grand River Aseptic Mfg Completes 90,000 Sq Ft Finishing And Warehouse Expansion
6 telling traits of a CDMO experienced in Annex 1 compliance
Grand River Aseptic Manufacturing (GRAM), a parenteral drug contract development and manufacturing organization (CDMO), held a sustainability celebration and a local park cleanup on April 21.
Grand River Aseptic Manufacturing (GRAM), a sterile injectable pharmaceutical contract manufacturer of biologics, small molecules, and vaccines, announced the approval of Bavarian Nordic’s recent Biologics License Application (BLA) supplement authorizing the manufacture of JYNNEOS. In conjunction with that approval, GRAM recently hosted a regulatory inspection by the Center for Biologics Evaluation and Research (CBER) that resulted in zero observations and Federal Drug Administration (FDA) approval of the company’s expanded filling facility and new finishing center.
MEMPHIS, Tenn.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its cell therapy contract development and manufacturing (CDMO) facility in Memphis, Tenn. The expanded space is suitable for clinical and commercial cell therapy manufacturing, with an additional nine (9) state-of-the-art processing suites, adding to an existing 16 cleanrooms.